Ginkgo Bioworks (DNA)
(Real Time Quote from BATS)
$0.28 USD
+0.01 (3.63%)
Updated Aug 12, 2024 10:30 AM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Ginkgo Bioworks Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 944 | 1,316 | 1,550 | 0 | 0 |
Receivables | 18 | 82 | 136 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 4 | 3 | 0 | 0 |
Other Current Assets | 40 | 47 | 34 | 0 | 0 |
Total Current Assets | 1,002 | 1,450 | 1,723 | 0 | 0 |
Net Property & Equipment | 188 | 315 | 146 | 0 | 0 |
Investments & Advances | 79 | 114 | 115 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 1 | 0 |
Intangibles | 132 | 171 | 43 | 0 | 0 |
Deposits & Other Assets | 58 | 89 | 44 | 0 | 0 |
Total Assets | 1,665 | 2,539 | 2,071 | 1 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 10 | 8 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 110 | 115 | 93 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 44 | 48 | 33 | 0 | 0 |
Total Current Liabilities | 164 | 173 | 135 | 1 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 158 | 175 | 175 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 22 | 0 | 0 |
Other Non-Current Liabilities | 24 | 42 | 172 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 568 | 803 | 504 | 1 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 6,386 | 6,136 | 3,805 | 0 | 0 |
Retained Earnings | -5,291 | -4,398 | -2,298 | 0 | 0 |
Other Equity | 1 | -3 | 60 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,097 | 1,736 | 1,567 | 0 | 0 |
Total Liabilities & Shareholder's Equity | 1,665 | 2,539 | 2,071 | 1 | 0 |
Total Common Equity | 1,097 | 1,736 | 1,567 | 0 | 0 |
Shares Outstanding | 2,001.30 | 1,939.90 | 1,690.90 | NA | NA |
Book Value Per Share | 0.55 | 0.90 | 0.93 | 0.00 | 0.00 |
Fiscal Year End for Ginkgo Bioworks Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,269 | 840 | 944 | 1,049 | 1,106 |
Receivables | 19 | 25 | 18 | 63 | 69 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 34 | 38 | 40 | 29 | 48 |
Total Current Assets | 783 | 903 | 1,002 | 1,142 | 1,223 |
Net Property & Equipment | 211 | 196 | 188 | 202 | 294 |
Investments & Advances | 62 | 76 | 79 | 86 | 121 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 91 | 125 | 132 | 158 | 164 |
Deposits & Other Assets | 60 | 61 | 58 | 97 | 98 |
Total Assets | 1,625 | 1,582 | 1,665 | 2,026 | 2,292 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 140 | 27 | 9 | 11 | 14 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 108 | 110 | 115 | 110 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 26 | 34 | 44 | 43 | 39 |
Total Current Liabilities | 166 | 169 | 164 | 168 | 163 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 153 | 166 | 158 | 170 | 180 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 21 | 24 | 32 | 34 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 792 | 594 | 568 | 774 | 788 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 6,508 | 6,445 | 6,386 | 6,334 | 6,281 |
Retained Earnings | -5,674 | -5,456 | -5,291 | -5,079 | -4,776 |
Other Equity | -2 | -2 | 1 | -3 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 833 | 987 | 1,097 | 1,253 | 1,504 |
Total Liabilities & Shareholder's Equity | 1,625 | 1,582 | 1,665 | 2,026 | 2,292 |
Total Common Equity | 100,832 | 987 | 1,097 | 1,253 | 1,504 |
Shares Outstanding | 2,211.20 | 2,033.60 | 2,001.30 | 1,972.70 | 2,085.50 |
Book Value Per Share | 45.60 | 0.49 | 0.55 | 0.64 | 0.72 |